St. George Medical is an innovative medical device company focused on interventional cardiology products. The company has developed proprietary medical device technology that has the potential to become the first-line treatment for patients suffering from abdominal aortic aneurysms, thoracic aortic aneurysms, mitral regurgitation, and coronary artery disease. St. George Medical’s flagship product, the Titan™AAA, was specifically developed to improve outcomes for patients diagnosed with abdominal aortic aneurysms. It received European CE Mark clearance in 2014, with US clinical trials to follow. In addition to the Titan™AAA, the company has 15 minimally invasive interventional cardiology products in the pipeline. For more information, visit www.StGeorgeMed.com.

1. Burke Hedges
Presents
Delivering Solutions Through Evolution
3700 Island Blvd Unit C–208
Aventura, FL 33160
www.stgeorgemed.com
info@stgeorgement.com

2. St.GeorgeMedicalConfidential
2
The Problem
Our Mission & Approach
The Market
Our Solutions
Our Team
Financials
Our Future
Agenda
1
2
3
4
5
6
7

3. St.GeorgeMedicalConfidential
3
Abdominal aortic aneurysm (AAA) rupture is the
3rd leading cause of death in men older than 60 in
the United States.
75% of AAA rupture patients bleed out before
reaching the hospital.
90% of AAA rupture patients bleed out before
reaching the operating table.
Current treatments have a 20% failure rate. Failure
can result in AAA rupture.
Many patients don’t qualify for current
treatments, or are told to wait until the risk of
death from rupture exceeds the risk of surgery.
Unmet Needs in the Treatment ofAbdominalAorticAneurysms
Death from AAA Rapture
 Death before reaching OR
 Death before reaching hospital
 Survivors

4. St.GeorgeMedicalConfidential
4
To create a device that would solve the 20% reoperation rate
associated with conventional stent-graft technology.
To develop additional minimally invasive medical products that
extend quality of life.
To form a team of world-renowned medical device experts and
entrepreneurs.
To lay the groundwork for sales and distribution in Europe, the US,
China, and India.
Launch 15 fully developed IP products through 2017 and become a
leader in the worldwide medical device market.
Our Mission

5. 5
St.GeorgeMedicalConfidential
Our Three Phase Approach
Phase I
Phase II
Phase III
Phase I
Develop Products and Strategic Partnerships
- 3 years (2011 – 2014)
 Develop solutions for the 20% reoperation
rate associated with AAA repair.
 Forge strategic partnerships and alliances.
 Get the CE Mark for products in Europe.
Phase II
Manufacturing and Sales - 2 Years (2014-
2016)
 Manufacture and sell products in Europe,
India, and China.
 Develop additional products.
 Begin clinical trials for the US market.
 Earn $100 million per year in sales with 20%
profits.
Phase III
Exit Strategy (2017)
 Sell intellectual property (IP) and cash out.
 Go public

6. St.GeorgeMedicalConfidential
6
Market Opportunity – AAA procedures in thousands
 10 million people are
diagnosed with aortic
aneurysm every year,
but in 2012, only
2.9% of patient were
treated.
 This primarily due to
limitations with the
current technology.
 Many patients are
not good candidates
for the procedure.
 Others are asked to
wait until the risk of
rupture exceeds the
risk of surgery.
Addressable Market

7. St.GeorgeMedicalConfidential
7
Titan AAA
Parodi
Prevents migration without
barbs for solid fixation,
faster healing, and reduced
failure rate.
Doesn’t block access to
important arteries.
Sealing ring prevents leaks
and failures.
Cage-free design doesn’t
interfere with normal
movement.
Adapts to any anatomy, so
more patients will qualify for
the procedure.
Provides stability and prevents
failure due to kinking.
• Patent Protected
Product
• Received European CE
Mark Clearance
Our Solution

8. Additional Problems in
Interventional Cardiology
St.GeorgeMedicalConfidential
8
Aortic disease is a silent epidemic that
kills approximately 47,000 Americans
every year.
Thoracic aortic aneurysm (TAA) rupture
is the 13th leading cause of death in the
United States.
Mitral Regurgitation (MR) is a life
threatening condition that will affect 5
million people by 2030.
Coronary heart disease is the leading
cause of death worldwide.

9. The Need for Minimally Invasive
Cardiovascular Treatments
St.GeorgeMedicalConfidential
9
Studies have shown that minimally invasive procedures can:
• Reduce mortality rates by as much as 67%.
• Shorten hospital stays by up to 76%.
• Reduce pain and scarring after surgery.
St. George Medical has developed the first minimally invasive treatments for
thoracic aortic aneurysms and mitral regurgitation.

10. Our Minimally Invasive Solutions
St.GeorgeMedicalConfidential
10
Thor TAA
Parodi
Prevents blog clots
in the artery, a
problem with
existing technology.
Corstent H Atlas TMV
The first minimally
invasive treatment
for TAA. Patent
approved in the US.
The first minimally
invasive alternative
treatment for Mitral
Regurgitation.

11. Our Competitive Advantage
St.GeorgeMedicalConfidential
11
Medtronic, Cook, Gore, Endologix, and other current market leaders use
antiquated self-expanding stent technology. St. George Medical is the first to
offer a balloon-expandable stent that offers the following advantages:
Current Technology
Self Expanding
• Lack of adjustability with 13+ sizes.
• Once deployed, the stent is not adjustable.
• Low radial strength makes it prone to migration.
• Uses anchoring barbs that damage the artery wall.
• No sealing ring.
• Fully-caged body with metal stent.
• Not suitable for difficult anatomies with short and
angled necks, so many patients don’t qualify for
the procedure.
• Prone to kinking.
Our Technology
Balloon Expanding
• Adjustable sizing that only requires 2 sizes.
• Adjustable and accurate deployment.
• High radial strength keeps the stent in place.
• Doesn’t require barbs for anchoring.
• Sealing ring to prevent leaks.
• Cage-free body doesn’t limit normal movement.
• Suitable for difficult anatomies because of the
adjustability, secure fixation, sealing ring, and
cage-free body.
• Increased stability prevents kinking.

12. Regulatory Strategy
St.GeorgeMedicalConfidential
12
Obtain European CE Mark clearance for each product.
• Done for Titan AAA in Q1 2014, Thor in 2015.
Sell and distribute
approved products in
Europe and emerging
markets.
At the same time,
complete US
clinical trials and
prepare for sales
and distribution.
Set up manufacturing
in the United States.

13. Intellectual Property
St.GeorgeMedicalConfidential
13
Our intellectual property includes 23 international and US
patents with 9 additional pending patent applications.

14. Our Founder
St.GeorgeMedicalConfidential
14
Dr. George L. de Goicoechea
CEO and Founder of St. George Medical, Inc.
• Inventor and entrepreneur in the cardiovascular device industry.
• Excels at making early-stage businesses profitable.
• Pioneered work on on the pacemaker, vascular grafts for surgical
bypass, and the first minimally invasive aortic aneurysm treatment.
• Previously launched 3 successful startups – Mintec sold to Boston
Scientific for $72 million.
• Father of the $2 billion per year aortic stent graft market.

15. Medical Advisory Board
St.GeorgeMedicalConfidential
15
Dr. Juan Carlos Parodi – Chairman of the Board
• Co-Inventor of the first endovascular stent graft to treat AAA.
• Revolutionized interventional cardiology.
• Holds key patents related to Titan AAA and Thor TAA.
Dr. Joseph Lamelas – Medical Board
• Chief of Cardiac Surgery at Mt. Sinai Medical Center in Miami.
• Performed more than 7000 open-heart procedures.
• Developing Atlas TMV – the first minimally invasive treatment for MR.
Dr. Eduardo de Marchena– Medical Board
• Professor of Medicine and Surgery at the University of Miami.
• Four-time recipient of the Best Cardiology Attending Award.
• Developing Corstent H - next generation coronary stent technology.
Dr. Claude Mialhe– Medical Board
• Inventor of the Introducer System for large caliber aortic stents.
• Two-time recipient of the Innovation Award in London.
• Developing the Mialhe Introducer System for the Titan AAA.

16. Management Team
St.GeorgeMedicalConfidential
16
Guro Bjornstad – Vice President of Clinical Development
• 20 years of experience bringing cardiovascular products to market.
• Oversees clinical development for all products at St. George Medical.
Gerald North, Esq. – Antitrust Litigation and Patent Lawsuits
• Experience and success in legal disputes related to AT&T, Gore, and Mintec.
• Oversees patent and legal matters for St. George Medical.
Burke Hedges – Vice President of Corporate Development
• 30 years of business experience with over 20 successful startups.
• Oversees business development for St. George Medical.
Bernhard Neuwirth – Vice President of Sales (Europe)
• Sales experience with prominent companies, including Boston Scientific and J&J.
• Oversees sales for St. George Medical in the European market.
Doug Berkoff – Chief Financial Officer
• 20 years of experience in financial operations management.
• Oversees financial matters for St. George Medical.
Frank Avellanet – Consultant
• 36 years of management experience in the medical device industry.
• Oversees worldwide manufacturing for St. George Medical.

17. Financials
St.GeorgeMedicalConfidential
17
5-Year Financial Projections

18. The Future of St. George Medical
St.GeorgeMedicalConfidential
18
St. George Medical recently entered Phase II of its three stage development plan.
The company has initiated the second round of equity funding to support
manufacturing and sales efforts.
With a strong IP portfolio and family of 15 medical device products, St. George Medical
is positioned to become a major player in the medical device industry.
We hope you enjoyed the presentation.
If you’re interested in learning more about St. George Medical, check out:
www.StGeorgeMed.com
If you’re interested in getting involved with the company in its early stages, check out:
www.stgeorgemed.com/investor-contact
A member of our team will get back to your shortly.